Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile

Journal of Alzheimer's Disease

Volumn 21, Issue 2, 2010, Pages 431-444

  Magini, Alessandro ^a   Urbanelli, Lorena ^a   Ciccarone, Virginia ^a   Tancini, Brunella ^a   Polidoro, Mario ^a   Timperio, Anna Maria ^b   Zolla, Lello ^b   Tedde, Andrea ^c   Sorbi, Sandro ^c   Emiliani, Carla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF TUSCIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; early markers; proteome analysis; skin fibroblasts

Indexed keywords

BIOLOGICAL MARKER; PRESENILIN 1; PROTEASOME; PROTEOME; UBIQUITIN;

ADULT; AGE; ALZHEIMER DISEASE; ARTICLE; BRAIN; CELL ADHESION; COGNITION; CONTROLLED STUDY; CYTOLYSIS; CYTOSKELETON; ENERGY; ENERGY METABOLISM; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MOTIVATION; MUTATION; NERVE DEGENERATION; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN BIOPSY; STRESS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 77957345098     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091522     Document Type: Article

References (95)

1. PariharMS,Hemnani T (2004) Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11, 456467.
2. Isacson O, Seo H, Lin L, Albeck D, Granholm AC (2002) Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci 25, 7984.
3. Torreilles F, Touchon J (2002) Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease. Prog Neurobiol 66, 191203.
4. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the betaamyloid precursor protein in familial Alzheimer's disease increases betaprotein production. Nature 360, 672674.
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, PericakVance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921923.
6. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697699.
7. LevyLahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973977.
8. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. (1995) Cloning of a gene bearing missense mutations in earlyonset familial Alzheimer's disease. Nature 375, 754760.
9. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: The implications of systematic metaanalyses. Nat Rev Neurosci 9, 768778.
10. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789791.
11. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387403.
12. Mc Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDSADRDA Work Group under the auspices ofDepartment ofHealth andHuman Services Task Force on Alzheimer's Disease. Neurology 34, 939944.
13. De Kosky ST,Marek K (2003) Looking backward tomove forward: Early detection of neurodegenerative disorders. Science 302, 830834.
14. Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S (1998) Peripheralmarkers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 12, 1734.
15. Khan TK, Alkon DL (2006) An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc Natl Acad Sci U S A 103, 1320313207.
16. Urbanelli L, Magini A, Ciccarone V, Trivelli F, Polidoro M, Tancini B, Emiliani C (2009) New perspectives for the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 4, 160181.
17. Nagasaka Y, Dillner K, Ebise H, Teramoto R, Nakagawa H, Lilius L, Axelman K, Forsell C, Ito A, Winblad B, Kimura T, Graff C (2005) A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers fromtheir wild-type siblings. Proc Natl Acad Sci U S A 102, 1485414859.
18. Emiliani C, Urbanelli L, Racanicchi L, Orlacchio A, Pelicci G, Sorbi S, Bernardi G (2003) Upregulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation. J Biol Chem 278, 3845338460.
19. Bellucci C, Lilli C, Baroni T, Parnetti L, Sorbi S, Emiliani C, Lumare E, Calabresi P, Balloni S, Bodo M (2007) Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med 13, 542550.
20. Urbanelli L, Emiliani C, Massini C, Persichetti E, Orlacchio A, Pelicci G, Sorbi S, Hasilik A, Bernardi G (2008) Cathepsin D expression is decreased in Alzheimer's disease fibroblasts. Neurobiol Aging 29, 1222.
21. Balin AK, Baker AC, Leong IC, Blass JP (1988) Normal replicative lifespan of Alzheimer skin fibroblasts. Neurobiol Aging 9, 195198.
22. Tesco G, Vergelli M, Amaducci L, Sorbi S (1993) Growth properties of familialAlzheimer skin fibroblasts during in vitro aging. Exp Gerontol 28, 5158.
23. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 72, 248254.
24. Gorg A, Postel W, Domscheit A, Gunther S (1988) Twodimensional electrophoresis with immobilized pH gradients of leaf proteins from barley (Hordeum vulgare): Method, reproducibility and genetic aspects. Electrophoresis 9, 681692.
25. Hochstrasser D, Augsburger V, Pun T, Weber D, Pellegrini C,Muller AF (1988) "Highresolution" minitwodimensional gel electrophoresis automatically run and stained in less than 6 h with small, readytouse slab gels. Clin Chem 34, 166170.
26. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) Ingel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1, 28562860.
27. Blass JP (1994) The cultured fibroblast model. J Neural Transm Suppl 44, 8795.
28. Connolly GP (1998) Fibroblast models of neurological disorders: Fluorescence measurement studies. Trends Pharmacol Sci 19, 171177.
29. Braak H, Braak E (1991) Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82, 239259.
30. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM (2006) Genetics, transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry 67, 652670.
31. Galloway PG, Mulvihill P, Siedlak S, Mijares M, Kawai M, Padget H, Kim R, Perry G (1990) Immunochemical demonstration of tropomyosin in the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 137, 291300.
32. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA (2009) Proteomicsdetermined differences in the concanavalin Afractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: Implications for progression of AD. J Proteome Res 8, 471482.
33. Silacci P,Mazzolai L,GauciC, StergiopulosN,Yin HL,Hayoz D (2004) Gelsolin superfamily proteins: Key regulators of cellular functions. Cell Mol Life Sci 61, 26142623.
34. Van Impe K, De Corte V, Eichinger-L, Bruyneel E, Mareel M, Vandekerckhove J, Gettemans J (2003) The Nucleocytoplasmic actinbinding protein CapG lacks a nuclear export sequence present in structurally related proteins. J Biol Chem 278, 1794517952.
35. Taoka M, Ichimura T,WakamiyaTsuruta A, Kubota Y, Araki T, Obinata T, Isobe T (2003) V1, a protein expressed transiently during murine cerebellar development, regulates actin polymerization via interaction with capping protein. J Biol Chem 278, 58645870.
36. Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269, 2080720810.
37. Joubert R, Caron M, Avellana Adalid V, Mornet D, Bladier D (1992) Human brain lectin: A soluble lectin that binds actin. J Neurochem 58, 200203.
38. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322, 11111122.
39. Gerke V, Weber K (1985) The regulatory chain in the p36kd substrate complex of viral tyrosinespecific protein kinases is related in sequence to the S100 protein of glial cells. EMBO J 4, 29172920.
40. Svenningsson P, Greengard P (2007) p11 (S100A10) - an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol 7, 2732.
41. Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJ (2009) Transglutaminases and neurodegeneration. J Neurochem 109(Suppl 1), 160166.
42. SanchezMejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, ScearceLevie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11, 13111318.
43. Zhu D, Lai Y, Shelat PB, Hu C, Sun GY, Lee JC (2006) Phospholipases A2 mediate amyloidbeta peptideinduced mitochondrial dysfunction. J Neurosci 26, 1111111119.
44. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, MuellerSteiner S, Devidze N, Wang X, Grubb A, Gan L (2008) Cystatin Ccathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247257.
45. Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL (1998) Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol Dis 5, 3745. (Pubitemid 28361650)
46. Zhao WQ, Ravindranath L, Mohamed AS, Zohar O, Chen GH, Lyketsos CG, Etcheberrigaray R, Alkon DL (2002) MAP kinase signaling cascade dysfunction specific to Alzheimer's disease in fibroblasts. Neurobiol Dis 11, 166183.
47. Mendonsa G, Dobrowolska J, Lin A, Vijairania P, Jong YJ, Baenziger NL (2009) Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts. PLoS One 4, e4655.
48. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD (2000) Calcium signaling in the ER: Its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 23, 222229.
49. Smith IF, Green KN, LaFerla FM (2005) Calcium dysregulation in Alzheimer's disease: Recent advances gained from genetically modified animals. Cell Calcium 38, 427437.
50. 2+ leak channels, a function disrupted by familial Alzheimer's diseaselinked mutations. Cell 126, 981993.
51. Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolato C (2006) Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium 39, 539550.
52. 2+ leak function of presenilin 1. J Clin Invest 117, 12301239.
53. Ogawa M, Fukuyama H, Ouchi Y, Yamauchi H, Kimura J (1996) Altered energy metabolism in Alzheimer's disease. J Neurol Sci 139, 7882.
54. Messier C, Gagnon M (2000) Glucose regulation and brain aging. J Nutr Health Aging 4, 208213.
55. Sultana R, BoydKimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27, 15641576.
56. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM,Klein JB, TurnerDM, Butterfield DA (2007)An increase in Sglutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85, 15061514.
57. Sultana R, BoydKimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11, 153164.
58. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinaserelated protein 2, alphaenolase and heat shock cognate 71. J Neurochem 82, 15241532.
59. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81128.
60. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18, 457461.
61. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4Hydroxynonenalderived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68, 20922097.
62. Markesbery WR, Lovell MA (1998) Fourhydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 3336.
63. Selley ML (1998) (E)4hydroxy2nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 25, 169174.
64. Burczynski ME, Sridhar GR, PalackalNT, Penning TM(2001) The reactive oxygen species-and Michael acceptorinducible human aldoketo reductase AKR1C1 reduces the alpha,betaunsaturated aldehyde 4hydroxy2nonenal to 1,4dihydroxy2nonene. J Biol Chem 276, 28902897.
65. Picklo MJ, Sr., Olson SJ, Hayes JD, Markesbery WR, Montine TJ (2001) Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Res 916, 229238.
66. Picklo MJ, Olson SJ, Markesbery WR, Montine TJ (2001) Expression and activities of aldoketo oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 60, 686695.
67. Nijtmans LG, de Jong L, Artal SanzM, Coates PJ, Berden JA, Back JW, Muijsers AO, van der Spek H, Grivell LA (2000) Prohibitins act as a membranebound chaperone for the stabilization of mitochondrial proteins. EMBO J 19, 24442451.
68. Tatsuta T,Model K, Langer T (2005) Formation ofmembranebound ring complexes by prohibitins in mitochondria. Mol Biol Cell 16, 248259.
69. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 4553.
70. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 109(Suppl 1), 153159.
71. PicciniA, FassioA, Pasqualetto E,VitaliA, BorghiR, Palmieri D, Nacmias B, Sorbi S, Sitia R, Tabaton M (2004) Fibroblasts from FADlinked presenilin 1 mutations display a normal unfolded protein response but overproduce Abeta42 in response to tunicamycin. Neurobiol Dis 15, 380386.
72. Paul S (2008) Dysfunction of the ubiquitinproteasome system in multiple disease conditions: Therapeutic approaches. Bioessays 30, 11721184.
73. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425479.
74. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D (1995) Amyloid betaprotein inhibits ubiquitindependent protein degradation in vitro. J Biol Chem 270, 1970219708.
75. LiuM, Reimschuessel R, Hassel BA(2002)Molecular cloning of the fish interferon stimulated gene, 15 kDa (ISG15) orthologue: A ubiquitinlike gene induced by nephrotoxic damage. Gene 298, 129139.
76. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxyterminal hydrolase L1. Free Radic Biol Med 33, 562571.
77. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and downregulation of ubiquitin carboxylterminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279, 1325613264.
78. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB,Martins RN (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. J Alzheimers Dis 10, 391397.
79. Rutkowski DT, Kaufman RJ (2004) A trip to the ER: Coping with stress. Trends Cell Biol 14, 2028.
80. Hoozemans JJ, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, Scheper W (2005) The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 110, 165172.
81. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, GeorgeHyslop PS, Tohyama M (2001) Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's diseaselinked presenilin1 mutations. J Biol Chem 276, 4344643454.
82. Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, Katayama T, Yoneda T,Morihara T, Yasuda Y, Takagi T, Kudo T, Tsuda T, Itoyama Y, Makifuchi T, Fraser PE, St GeorgeHyslop P, Tohyama M (2001) Increased production of betaamyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 276, 21082114.
83. Wang P, Heitman J (2005) The cyclophilins. Genome Biol 6, 226.
84. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R (2006) Pin1 in Alzheimer's disease. J Neurochem 98, 16971706.
85. Egeo A, Mazzocco M, Arrigo P, VidalTaboada JM, Oliva R, Pirola B, Giglio S, RasoreQuartino A, Scartezzini P (1998) Identification and characterization of a new human gene encoding a small protein with high homology to the prolinerich region of the SH3BGR gene. Biochem Biophys Res Commun 247, 302306. (Pubitemid 28420817)
86. Mazzocco M, Arrigo P, Egeo A,Maffei M, Vergano A, Di Lisi R, Ghiotto F, Ciccone E, Cinti R, Ravazzolo R, Scartezzini P (2001) A novel human homologue of the SH3BGR gene encodes a small protein similar to Glutaredoxin 1 of Escherichia coli. Biochem Biophys Res Commun 285, 540545.
87. Cesareni G, Panni S, Nardelli G, Castagnoli L (2002) Can we infer peptide recognition specificity mediated by SH3 domains? FEBS Lett 513, 3844.
88. Berleth ES, Nadadur S, Henn AD, Eppolito C, Shiojiri S, Gurtoo HL, EhrkeMJ,Mihich E (1999) Identification, characterization, and cloning of TIPB1, a novel protein inhibitor of tumor necrosis factorinduced lysis. Cancer Res 59, 54975506.
89. Xu C, Zheng P, Shen S, Xu Y, Wei L, Gao H, Wang S, Zhu C, Tang Y, Wu J, Zhang Q, Shi Y (2005) NMR structure and regulated expression in APL cell of human SH3BGRL3. FEBS Lett 579, 27882794.
90. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5, 45.
91. Benveniste EN, Nguyen VT, O'Keefe GM (2001) Immunological aspects ofmicroglia: Relevance to Alzheimer's disease. Neurochem Int 39, 381391.
92. Goodman AB (2006) Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 209, 598603.
93. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, De Strooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the betasecretase BACE1. Science 314, 664666.
94. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease friend or foe? Trends Neurosci 32, 619628.
95. Tsuboi Y, Kakimoto K, Nakajima M, Akatsu H, Yamamoto T, Ogawa K, Ohnishi T, Daikuhara Y, Yamada T (2003) Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease. Acta Neurol Scand 107, 8186.